If you’ve ever attempted to get to the bottom of a suspected chronic infection, you’ve likely encountered the ongoing debate between direct and indirect testing. Understanding the distinction isn’t just academic—it’s critical to making accurate diagnoses and effective treatment decisions.
Both methods can provide valuable information, but they operate at different levels of biological evidence. Direct testing seeks to identify the pathogen itself, while indirect testing detects your immune system’s response to it. Knowing which to prioritize—and when—can mean the difference between clarity and ongoing uncertainty.
Direct Testing: Identifying the Pathogen Itself
Direct testing aims to detect the actual presence of a pathogen in the body—whether that’s microbial DNA, RNA, proteins, or intact organisms. It offers the highest level of diagnostic confirmation, and is typically preferred when making treatment decisions, as it confirms that the organism is currently present.
Common direct methods include:
- PCR (Polymerase Chain Reaction):
This technique amplifies microbial DNA to detectable levels, making it highly specific and sensitive, especially when an infection is active.
PCR is available through a variety of labs, including the DNA Connexions Lyme Panel, which uses a urine sample to test for DNA from Borrelia, Babesia, Bartonella, Ehrlichia, and other vector-borne pathogens.
PCR may still miss infections if the microbes are hidden in tissue or biofilms and not shedding into the sampled fluid at the time of collection. - Culture:
Considered the gold standard in conventional infectious disease medicine because it allows for isolation and identification of live organisms. However, culturing vector-borne infections (VBIs) like Bartonella, Borrelia, and Babesia is notoriously difficult.
These organisms are often slow-growing, intracellular, or biofilm-forming, which makes them hard to culture using standard techniques.
This culturing difficulty is a major reason why many infectious disease specialists struggle to validate or diagnose chronic forms of these infections—they simply don’t grow well using the gold standard method. - FISH (Fluorescent In-Situ Hybridization):
FISH testing uses fluorescent probes that bind to the genetic material of specific pathogens, allowing for direct visualization under a microscope.
It is especially useful for detecting organisms in blood smears, even when present in low quantities.
IGeneX offers FISH testing for both Bartonella and Babesia, providing an important tool for clinicians dealing with suspected chronic infections.
Like PCR, FISH confirms active presence of the organism—but may also be limited by where and when the pathogen is present in the body.
Indirect Testing: Measuring the Host Response
Indirect testing evaluates immune system responses rather than looking for the pathogen itself. These tests infer the presence of an infection based on patterns of immune activation or memory, and can be helpful when direct detection methods are inconclusive.
Common indirect methods include:
- Antibody Testing (IgM, IgG, IgA): Measures immune memory and recent immune responses. Interpretation can be complex due to persistent antibody elevation or cross-reactivity.
- T-Cell Response Assays (e.g., Elispot): Measure cell-mediated immune activity, often reflecting an ongoing immune response not captured by antibodies alone.
- Cytokine Panels & Inflammatory Biomarkers: These offer insight into generalized immune activation but are nonspecific.
The main limitation with indirect testing is that it cannot definitively confirm the presence of a pathogen—only that the immune system has responded to it at some point. This makes it vulnerable to both false positives (from past exposures, autoimmunity, or cross-reactivity) and false negatives (due to immunosuppression or immune exhaustion).
Why Direct Testing Is Clinically Preferred
In my clinical experience, when high-quality direct testing is available, it consistently provides the most actionable data. Direct evidence of a pathogen’s presence allows for more targeted and confident treatment decisions.
Indirect testing can be helpful—especially in cases where no clear pathogen is identified—but it is ultimately a secondary measure, best used to support or contextualize findings rather than as a standalone diagnostic tool.
I’ve seen numerous cases where indirect tests were falsely positive or falsely negative compared to reliable direct testing. In some situations, indirect markers suggested a strong immune response to an infection that was no longer present, leading to unnecessary or prolonged treatment. In other cases, indirect tests missed active infections entirely due to immune dysfunction or suppression. (See link for article)
________________
**Comment**
And yet, indirect testing remains the accepted testing for all tick-borne illness despite being abysmal.
In fact, there’s been a concerted effort to suppress direct testing. This, is the first red flag one experiences in Lymeland. Why would public health ‘authorities’ suppress an accurate test? And yet, here we are.
For more:
- https://madisonarealymesupportgroup.com/2018/09/12/lyme-testing-problems-solutions/
- https://madisonarealymesupportgroup.com/2026/03/18/understanding-tick-borne-disease-testing-in-2026/
- https://madisonarealymesupportgroup.com/2025/10/09/inside-igenexs-new-lyme-test/
- https://madisonarealymesupportgroup.com/2018/01/16/2-tier-lyme-testing-missed-85-7-of-patients-milford-hospital/
- https://madisonarealymesupportgroup.com/2018/08/15/milford-pathologist-fires-broadside-at-cdc-motion-to-discuss/
- https://madisonarealymesupportgroup.com/2018/10/13/direct-test-for-ld-carl-tuttle-chews-up-cdc-spits-them-out/
